Bvf Partners L P/Il bought 1,927,937 shares (SEC Form 4)

5/13/24 5:04:15 PM ET

$ELDN

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ELDN alert in real time by email

SEC FORM 4 SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BVF PARTNERS L P/IL

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FL

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Eledon Pharmaceuticals, Inc. [ ELDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
05/09/2024

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, $0.001 par value⁽¹⁾	05/09/2024		P		1,031,385⁽²⁾⁽³⁾	A	⁽²⁾⁽³⁾	3,361,803	D⁽⁵⁾
Common Stock, $0.001 par value⁽¹⁾	05/09/2024		P		821,121⁽²⁾⁽³⁾	A	⁽²⁾⁽³⁾	2,633,679	D⁽⁶⁾
Common Stock, $0.001 par value⁽¹⁾	05/09/2024		P		75,431⁽²⁾⁽³⁾	A	⁽²⁾⁽³⁾	220,460	D⁽⁷⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Pre-funded Warrants to Purchase Common Stock⁽¹⁾	$0.001	05/09/2024		P		3,173,135		⁽²⁾⁽⁴⁾	⁽²⁾⁽⁴⁾	Common Stock, $0.001 par value	3,173,135	⁽²⁾⁽⁴⁾	3,173,135	D⁽⁵⁾
Pre-funded Warrants to Purchase Common Stock⁽¹⁾	$0.001	05/09/2024		P		2,526,238		⁽²⁾⁽⁴⁾	⁽²⁾⁽⁴⁾	Common Stock, $0.001 par value	2,526,238	⁽²⁾⁽⁴⁾	2,526,238	D⁽⁶⁾
Pre-funded Warrants to Purchase Common Stock⁽¹⁾	$0.001	05/09/2024		P		232,068		⁽²⁾⁽⁴⁾	⁽²⁾⁽⁴⁾	Common Stock, $0.001 par value	232,068	⁽²⁾⁽⁴⁾	232,068	D⁽⁷⁾
Series X Convertible Preferred⁽¹⁾	⁽⁸⁾							⁽⁸⁾	⁽⁸⁾	Common Stock, $0.001 par value	122,833⁽¹⁰⁾		2,211	D⁽⁵⁾
Series X Convertible Preferred⁽¹⁾	⁽⁸⁾							⁽⁸⁾	⁽⁸⁾	Common Stock, $0.001 par value	96,611⁽¹⁰⁾		1,739	D⁽⁶⁾
Series X Convertible Preferred⁽¹⁾	⁽⁸⁾							⁽⁸⁾	⁽⁸⁾	Common Stock, $0.001 par value	19,222⁽¹⁰⁾		346	D⁽⁷⁾
Series X1 Convertible Preferred⁽¹⁾	⁽⁹⁾							⁽⁹⁾	⁽⁹⁾	Common Stock, $0.001 par value	3,214,437⁽¹⁰⁾		57,860	D⁽⁵⁾
Series X1 Convertible Preferred⁽¹⁾	⁽⁹⁾							⁽⁹⁾	⁽⁹⁾	Common Stock, $0.001 par value	2,374,987⁽¹⁰⁾		42,750	D⁽⁶⁾
Series X1 Convertible Preferred⁽¹⁾	⁽⁹⁾							⁽⁹⁾	⁽⁹⁾	Common Stock, $0.001 par value	424,169⁽¹⁰⁾		7,635	D⁽⁷⁾
Warrants to Purchase Common Stock⁽¹⁾	$12.96⁽¹⁰⁾							⁽¹¹⁾	07/14/2025	Common Stock, $0.001 par value	79,500⁽¹⁰⁾		79,500⁽¹⁰⁾	D⁽⁵⁾
Warrants to Purchase Common Stock⁽¹⁾	$12.96⁽¹⁰⁾							⁽¹¹⁾	07/14/2025	Common Stock, $0.001 par value	64,549⁽¹⁰⁾		64,549⁽¹⁰⁾	D⁽⁶⁾
Warrants to Purchase Common Stock⁽¹⁾	$12.96⁽¹⁰⁾							⁽¹¹⁾	07/14/2025	Common Stock, $0.001 par value	11,415⁽¹⁰⁾		11,415⁽¹⁰⁾	D⁽⁷⁾
Warrants to Purchase Series X1 Convertible Preferred Stock⁽¹⁾	$8,962.74⁽¹⁰⁾							⁽¹²⁾	09/14/2025	Series X1 Convertible Preferred Stock, $0.001 par value	1,453,000⁽¹⁰⁾		1,453	D⁽⁵⁾
Warrants to Purchase Series X1 Convertible Preferred Stock⁽¹⁾	$8,962.74⁽¹⁰⁾							⁽¹²⁾	09/14/2025	Series X1 Convertible Preferred Stock, $0.001 par value	1,086,000⁽¹⁰⁾		1,086	D⁽⁶⁾
Warrants to Purchase Series X1 Convertible Preferred Stock⁽¹⁾	$8,962.74⁽¹⁰⁾							⁽¹²⁾	09/14/2025	Series X1 Convertible Preferred Stock, $0.001 par value	189,000⁽¹⁰⁾		189	D⁽⁷⁾
Pre-funded Warrants to Purchase Common Stock⁽¹⁾	$0.001							⁽¹³⁾	12/31/2030	Common Stock, $0.001 par value	254,666		254,666	D⁽⁵⁾
Pre-funded Warrants to Purchase Common Stock⁽¹⁾	$0.001							⁽¹³⁾	12/31/2030	Common Stock, $0.001 par value	200,245		200,245	D⁽⁶⁾
Pre-funded Warrants to Purchase Common Stock⁽¹⁾	$0.001							⁽¹³⁾	12/31/2030	Common Stock, $0.001 par value	39,938		39,938	D⁽⁷⁾
Pre-funded Warrants to Purchase Common Stock⁽¹⁾	$0.001							⁽¹⁴⁾⁽¹⁵⁾	⁽¹⁴⁾⁽¹⁵⁾	Common Stock, $0.001 par value	2,028,645		2,028,645	D⁽⁵⁾
Pre-funded Warrants to Purchase Common Stock⁽¹⁾	$0.001							⁽¹⁴⁾⁽¹⁵⁾	⁽¹⁴⁾⁽¹⁵⁾	Common Stock, $0.001 par value	1,609,063		1,609,063	D⁽⁶⁾
Pre-funded Warrants to Purchase Common Stock⁽¹⁾	$0.001							⁽¹⁴⁾⁽¹⁵⁾	⁽¹⁴⁾⁽¹⁵⁾	Common Stock, $0.001 par value	165,950		165,950	D⁽⁷⁾
Warrants to Purchase Common Stock⁽¹⁾	$3							⁽¹⁴⁾⁽¹⁶⁾	⁽¹⁴⁾⁽¹⁶⁾	Common Stock, $0.001 par value	3,084,090		3,084,090	D⁽⁵⁾
Warrants to Purchase Common Stock⁽¹⁾	$3							⁽¹⁴⁾⁽¹⁶⁾	⁽¹⁴⁾⁽¹⁶⁾	Common Stock, $0.001 par value	2,446,209		2,446,209	D⁽⁶⁾
Warrants to Purchase Common Stock⁽¹⁾	$3							⁽¹⁴⁾⁽¹⁶⁾	⁽¹⁴⁾⁽¹⁶⁾	Common Stock, $0.001 par value	252,291		252,291	D⁽⁷⁾

1. Name and Address of Reporting Person^*

BVF PARTNERS L P/IL

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FL

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

BIOTECHNOLOGY VALUE FUND L P

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FL

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director		10% Owner
Officer (give title below)	X	Other (specify below)
		See Explanation of Responses

1. Name and Address of Reporting Person^*

BVF I GP LLC

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FL

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director		10% Owner
Officer (give title below)	X	Other (specify below)
		See Explanation of Responses

1. Name and Address of Reporting Person^*

BIOTECHNOLOGY VALUE FUND II LP

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FL

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director		10% Owner
Officer (give title below)	X	Other (specify below)
		See Explanation of Responses

1. Name and Address of Reporting Person^*

BVF II GP LLC

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FL

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director		10% Owner
Officer (give title below)	X	Other (specify below)
		See Explanation of Responses

1. Name and Address of Reporting Person^*

Biotechnology Value Trading Fund OS LP

(Last)

(First)

(Middle)

P.O. BOX 309 UGLAND HOUSE

(Street)

GRAND CAYMAN

KY1-1104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director		10% Owner
Officer (give title below)	X	Other (specify below)
		See Explanation of Responses

1. Name and Address of Reporting Person^*

BVF Partners OS Ltd.

(Last)

(First)

(Middle)

P.O. BOX 309 UGLAND HOUSE

(Street)

GRAND CAYMAN

KY1-1104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director		10% Owner
Officer (give title below)	X	Other (specify below)
		See Explanation of Responses

1. Name and Address of Reporting Person^*

BVF GP HOLDINGS LLC

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FL

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

BVF INC/IL

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FL

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

LAMPERT MARK N

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FL

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

Explanation of Responses:

1. This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Exchange Act") that collectively beneficially owns over 10% of the Issuer's outstanding shares of Common Stock (the "Common Stock"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

2. Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the "2024 Purchasers"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the "2024 Private Placement") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the "2024 Pre-Funded Warrants") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share.

3. Shares of Common Stock purchased in the 2024 Private Placement.

4. 2024 Pre-Funded Warrants purchased in the 2024 Private Placement. The 2024 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2024 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions.

5. Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

6. Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

7. Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

8. The Series X Convertible Preferred Stock may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d), more than 9.99% of the shares of Common Stock outstanding immediately after giving effect to such exercise. Each share of Series X Convertible Preferred Stock is convertible into 55.55 shares of Common Stock. The Series X Convertible Preferred Stock does not have an expiration date and is subject to certain adjustments pursuant to the Series X Exchange Agreement filed as Exhibit 10.1 to Form 8-K filed by the Issuer with the Securities and Exchange Commission on January 7, 2021.

9. The Series X1 Convertible Preferred Stock may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d), more than 9.99% of the shares of Common Stock outstanding immediately after giving effect to such exercise. Each share of Series X1 Convertible Preferred Stock is convertible into 55.55 shares of Common Stock. The Series X1 Convertible Preferred Stock does not have an expiration date and is subject to certain adjustments pursuant to the Series X1 Exchange Agreement filed as Exhibit 10.1 to Form 8-K filed by the Issuer with the Securities and Exchange Commission on January 13, 2022.

10. Reflects a one-for-eighteen reverse stock split of the Issuer's issued and outstanding Common Stock, effective as of October 5, 2020 (the "Stock Split").

11. Pursuant to a warrant exercise agreement between the Issuer and the Reporting Persons, the Issuer issued to the Reporting Persons warrants to purchase shares of Common Stock at an exercise price of $0.72 per share, with an exercise period of five and a half years (July 14, 2025). The warrants are subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting the Common Stock. The warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with the Exchange Act, more than 9.99% of Common Stock, subject to certain exceptions. In connection with the Stock Split, the exercise price was adjusted to $12.96.

12. Pursuant to a purchase agreement between the Issuer and the Reporting Persons, the Issuer issued to the Reporting Persons warrants to purchase shares of the Series X1 Convertible Preferred Stock at an exercise price of $497.93 per share, with an exercise period of five years (September 14, 2025). Each warrant to purchase shares of the Series X1 Convertible Preferred Stock is convertible into 1 share of Series X1 Convertible Preferred Stock, which is convertible into 1,000 shares of Common Stock. The warrants are subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting the Common Stock. The warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of Common Stock, subject to certain exceptions. In connection with the Stock Split, the exercise price was adjusted to $8,962.74.

13. Pursuant to a warrant exchange agreement between the Issuer and the Reporting Persons, the Issuer issued to the Reporting Persons warrants to purchase shares of Common Stock at an exercise price equal to $0.001 per share, with an exercise period of ten years (December 31, 2030). Each warrant to purchase shares of the Common Stock is convertible into 1 share of Common Stock. The warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of Common Stock, subject to certain exceptions.

14. Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the "2023 Purchasers"), the Issuer agreed to issue and sell to the 2023 Purchasers in a private placement (the "2023 Private Placement"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the "2023 Pre-Funded Warrants"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the "Common Warrants") at a per share purchase price equal to $2.31 (less $0.001 for each 2023 Pre-Funded Warrant, as applicable).

15. 2023 Pre-Funded Warrants purchased in the 2023 Private Placement. The 2023 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2023 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions.

16. Common Warrants purchased in the 2023 Private Placement. The Common Warrants are exercisable immediately and have a term of exercise equal to five years. The Common Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions.

	BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	05/13/2024
	Biotechnology Value Fund, L.P., By: BVF I GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer	05/13/2024
	BVF I GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer	05/13/2024
	Biotechnology Value Fund II, L.P., By: BVF II GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer	05/13/2024
	BVF II GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer	05/13/2024
	BVF Partners OS Ltd., By: BVF Partners L.P., its sole member, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	05/13/2024
	Biotechnology Value Trading Fund OS LP, By: BVF Partners L.P., its investment manager, BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	05/13/2024
	BVF GP Holdings LLC, By: /s/ Mark N. Lampert, Chief Executive Officer	05/13/2024
	BVF Inc., By: /s/ Mark N. Lampert, President	05/13/2024
	/s/ Mark N. Lampert	05/13/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $ELDN alert in real time by email

Date	Price Target	Rating	Analyst
5/13/2022	$25.00 → $15.00	Overweight	Cantor Fitzgerald
11/24/2021	$35.00 → $25.00	Buy	HC Wainwright & Co.

Bvf Partners L P/Il bought 1,927,937 shares (SEC Form 4)

Chat with this insight

Recent Analyst Ratings for $ELDN

$ELDN Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Bvf Partners L P/Il bought 1,927,937 shares (SEC Form 4)

$ELDN Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Eledon Pharmaceuticals Inc.

SEC Form SC 13G filed by Eledon Pharmaceuticals Inc.

SEC Form SC 13G filed by Eledon Pharmaceuticals Inc.

$ELDN SEC Filings

SEC Form 10-Q filed by Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 424B5 filed by Eledon Pharmaceuticals Inc.

$ELDN Leadership Updates

Live Leadership Updates

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

$ELDN Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cantor Fitzgerald resumed coverage on Eledon Pharmaceuticals with a new price target

HC Wainwright & Co. reiterated coverage on Eledon Pharmaceuticals with a new price target

SVB Leerink reiterated coverage on Eledon Pharmaceuticals with a new price target

$ELDN Financials

Live finance-specific insights

Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results

Eledon Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

$ELDN Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Large owner Bvf Partners L P/Il

SEC Form 4 filed by President Perrin Steven

SEC Form 4 filed by Chief Executive Officer Gros David-Alexandre C

$ELDN Press Releases

Fastest customizable press release news feed in the world

$ELDN Market Insights

Live Market Insights

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

HC Wainwright & Co. Reiterates Buy on Eledon Pharma, Maintains $16 Price Target

Eledon Pharmaceuticals Presents Updated Data On Tegoprubart For Preventing Organ Rejection In Kidney Transplant Patients At American Transplant Congress

12 Health Care Stocks Moving In Friday's After-Market Session

Recent Analyst Ratings for
$ELDN

$ELDN
Insider Purchases

$ELDN
Large Ownership Changes

$ELDN
SEC Filings

$ELDN
Leadership Updates

$ELDN
Analyst Ratings

$ELDN
Financials

$ELDN
Insider Trading

$ELDN
Press Releases

$ELDN
Market Insights